Advances in clinical and radiological studies of multidrug-resistant Acinetobacter baumannii pneumonia

doi:10.19871/j.cnki.xfcrbzz.2025.05.014

Abstract

Abstract: Acinetobacter baumannii (Ab) is an opportunistic Gram-negative pathogen that is widely distributed in both natural and medical environments. It has strong survival and adaptability capabilities and is a common pathogen causing nosocomial infections. This bacterium possesses multiple intrinsic drug-resistance genes, and coupled with the overuse of antibiotics in recent years, carbapenem-resistant Acinetobacter baumannii (CR-Ab) and multidrug-resistant Acinetobacter baumannii (MDR-Ab) have become widespread globally, with MDR-Ab posing a serious threat to human health. Due to the limited treatment options and poor prognosis of MDR-Ab pneumonia in clinical practice, along with its high mortality rate, it has long been a challenging issue for the global medical community. In this clinical predicament, early and accurate diagnosis plays a crucial role in the effective treatment and improved prognosis of MDR-Ab pneumonia. With the continuous development of imaging technology, imaging, as a non-invasive diagnostic method, can promptly detect can promptly detect MDR-Ab pneumonia and extrapulmonary manifestations, playing an irreplaceable role in the early identification, disease assessment, and treatment monitoring of MDR-Ab pneumonia. The application of artificial intelligence technology in imaging analysis also provides new approaches for early diagnosis and prognosis assessment. This paper reviews the latest progress in etiology, clinical characteristics, and imaging findings of MDR-Ab pneumonia at home and abroad, and discusses the application value of artificial intelligence in it.

Key words: Pneumonia, Acinetobacter baumannii, Multidrug-resistant, Computed tomography, Medical image

CLC Number:

R563.1

Wang Jie, Fan Bing. Advances in clinical and radiological studies of multidrug-resistant Acinetobacter baumannii pneumonia[J]. Electronic Journal of Emerging Infectious Diseases, 2025, 10(5): 73-78.

References

[1] PELEG AY, SEIFERT H, PATERSON DL.Acinetobacter baumannii:emergence of a successful pathogen[J]. Clin Microbiol Rev, 2008, 21(3):538-582.
[2] MORRIS FC, DEXTER C, KOSTOULIAS X, et al.The Mechanisms of Disease Caused by Acinetobacter baumannii[J]. Front Microbiol, 2019,17(10):1601.
[3] MORTENSEN BL, SKAAR EP.Host-microbe interactions that shape the pathogenesis of Acinetobacter baumannii infection[J]. Cell Microbiol, 2012, 14(9):1336-1344.
[4] 翟若南, 吴安华. 世界卫生组织《2024年细菌类重点病原体目录》[J]. 中国感染控制杂志, 2024, 23(6):782-783.
[5] BOUCHER HW, TALBOT GH, BRADLEY JS, et al.Bad bugs, no drugs:no ESKAPE! An update from the Infectious Diseases Society of America[J]. Clin Infect Dis, 2009, 48(1):1-12.
[6] ZILBERBERG MD, NATHANSON BH, SULHAM K, et al.Multidrug resistance, inappropriate empiric therapy, and hospital mortality in Acinetobacter baumannii pneumonia and sepsis[J]. Crit Care, 2016, 20(1):221.
[7] MOHD SAZLLY LIM S, ZAINAL ABIDIN A, LIEW SM, et al. The global prevalence of multidrug-resistance among Acinetobacter baumannii causing hospital-acquired and ventilator-associated pneumonia and its associated mortality:A systematic review and meta-analysis[J]. J Infect, 2019, 79(6):593-600.
[8] HARDING CM, HENNON SW, FELDMAN MF.Uncovering the mechanisms of Acinetobacter baumannii virulence[J]. Nat Rev Microbiol, 2018, 16(2):91-102.
[9] ESPINAL P, MARTÍ S, VILA J.Effect of biofilm formation on the survival of Acinetobacter baumannii on dry surfaces[J]. J Hosp Infect, 2012, 80(1):56-60.
[10] HASSAN KA, JACKSON SM, PENESYAN A, et al.Transcriptomic and biochemical analyses identify a family of chlorhexidine efflux proteins[J]. Proc Natl Acad Sci USA, 2013, 110(50):20254-20259.
[11] LEE HW, KOH YM, KIM J, et al.Capacity of multidrug-resistant clinical isolates of Acinetobacter baumannii to form biofilm and adhere to epithelial cell surfaces[J]. Clin Microbiol Infect, 2008, 14(1):49-54.
[12] HARDING CM, TRACY EN, CARRUTHERS MD, et al.Acinetobacter baumannii strain M2 produces type IV pili which play a role in natural transformation and twitching motility but not surface-associated motility[J]. mBio, 2013, 4(4):e00360-13.
[13] WILHARM G, PIESKER J, LAUE M, et al.DNA uptake by the nosocomial pathogen Acinetobacter baumannii occurs during movement along wet surfaces[J]. J Bacteriol, 2013, 195(18):4146-4153.
[14] BENTANCOR LV, CAMACHO-PEIRO A, BOZKURT-GUZEL C, et al.Identification of Ata, a multifunctional trimeric autotransporter of Acinetobacter baumannii[J]. J Bacteriol, 2012, 194(15):3950-3960.
[15] JUTTUKONDA LJ, CHAZIN WJ, SKAAR EP.Acinetobacter baumannii Coordinates Urea Metabolism with Metal Import To Resist Host-Mediated Metal Limitation[J]. mBio, 2016, 7(5):e01475-16.
[16] 蔺飞, 杜冰洁, 高灿, 等. 鲍曼不动杆菌生物被膜对抗菌药物耐药性的影响[J]. 中国感染控制杂志, 2018, 17(1):1-5.
[17] 陈寅, 栾和伟. 某院耐碳青霉烯类鲍曼不动杆菌的耐药性分析[J]. 临床检验杂志, 2022, 40(2):129-131.
[18] 陈娇, 刘康, 李剑平, 等. 鲍曼不动杆菌RND主动外排泵的表达与耐药性的关系[J]. 中国感染控制杂志, 2018, 17(11):951-957.
[19] KAKUTA N, NAKANO R, NAKANO A, et al.A novel mismatched pcr-restriction fragment length polymorphism assay for rapid detection of gyra and parc mutations associated with fluoroquino‐lone Resistance in Acinetobacter baumannii[J]. Ann Lab Med, 2020, 40(1):27-32.
[20] 杨艳, 王厚照, 张玲. 多重耐药鲍曼不动杆菌氨基糖苷类修饰酶与16S rRNA甲基化酶基因的研究[J]. 微生物学杂志, 2017, 37(4):28-33.
[21] CAPASSO R, PINTO A, SERRA N, et al.Alert Germ Infections: Chest X-ray and CT Findings in Hospitalized Patients Affected by Multidrug-Resistant Acinetobacter baumannii Pneumonia[J]. Tomography, 2022, 8(3): 1534-1543.
[22] LEUNG WS, CHU CM, TSANG KY, et al.Fulminant community-acquired Acinetobacter baumannii pneumonia as a distinct clinical syndrome[J]. Chest, 2006, 129(1):102-109.
[23] DEXTER C, MURRAY GL, PAULSEN IT, et al.Community-acquired Acinetobacter baumannii:clinical characteristics, epidemiology and pathogenesis[J]. Expert Rev Anti Infect Ther, 2015, 13(5):567-573.
[24] PATAMATAMKUL S, KLUNGBOONKRONG V, PRAISARNTI P, et al.A case-control study of community-acquired Acinetobacter baumannii pneumonia and melioidosis pneumonia in northeast Thailand:an emerging fatal disease with unique clinical features[J]. Diagn Microbiol Infect Dis, 2017, 87(1):79-86
[25] 王鹏, 宋秋鸣. 预测重症肺炎患者发生鲍曼不动杆菌多重耐药的风险列线图模型建立[J]. 中国抗生素杂志, 2022, 47(4):399-404.
[26] FALAGAS ME, KARVELI EA, KELESIDIS I, et al.Community-acquired Acinetobacter infections[J]. Eur J Clin Microbiol Infect Dis, 2007, 26(12):857-868.
[27] 梁庄万, 张群, 蒋秋燕, 等. 重症监护室老年感染性疾病病原菌分布及耐药性分析[J/CD]. 新发传染病电子杂志, 2021, 6(2):97-100.
[28] ALMOGHRABI Y, DAGHISTANI H, NIYAZI HA, et al.Epidemiological and Clinical Insights into Acinetobacter baumannii:A Six-Year Study on Age, Antibiotics, and Specimens[J]. Int J Gen Med, 2024, 17:5715-5725.
[29] SON HJ, CHO EB, BAE M, et al. Clinical and Microbiological Analysis of Risk Factors for Mortality in Patients With Carbapenem-Resistant Acinetobacter baumannii Bacteremia[J]. Open Forum Infect Dis, 2020, 7(10):ofaa378.
[30] LIU B, LI S, LI HT, et al.Outcomes and prognostic factors of tigecycline treatment for hospital-acquired pneumonia involving multidrug-resistant Acinetobacter baumannii[J]. J Int Med Res, 2020, 48(4):1-10
[31] 信瑞强, 李艳翠, 甄根深, 等. 鲍曼不动杆菌肺感染影像学特征分析[J]. 中国医学影像学杂志, 2017, 25(10):748-750.
[32] ZENG Z, WU J, QIN G, et al.Using time-series chest radiographs and laboratory data by machine learning for identifying pulmonary infection and colonization of Acinetobacter baumannii[J]. Respir Res, 2024, 25(1):2.
[33] HAROON A, HIGA F, FUJITA J, et al.Pulmonary computed tomography findings in 39 cases of Streptococcus pneumoniae pneumonia[J]. Intern Med, 2012, 51(24):3343-3349.
[34] TANAKA N, EMOTO T, SUDA H, et al.Community-acquired pneumonia: a correlative study between chest radiographic and HRCT findings[J]. Jpn J Radiol. 2015, 33(6):317-328.
[35] CHEN A, KARWOSKI RA, GIERADA DS, et al.Quantitative CT Analysis of Diffuse Lung Disease[J]. RadioGraphics, 2020, 40(1):28-43.
[36] 肖鑫. 鲍曼不动杆菌肺炎CT定量与临床特征相关研究[D]. 衡阳:南华大学, 2023.
[37] 穆婧, 王军大, 杨雅淋, 等. 鲍曼不动杆菌肺炎多种CT征象的多因素分析[J]. 中国CT和MRI杂志, 2023, 21(1):62-65.
[38] 王亚丽, 吴峰, 胡锋, 等. 多重耐药鲍曼不动杆菌下呼吸道感染的临床特点及药敏分析[J]. 临床肺科杂志, 2017, 22(3):479-483.
[39] 陈丽莉. 鲍曼不动杆菌感染后继发性机化性肺炎一例[J]. 江苏医药, 2015, 41(21):2606-2607, 2506.
[40] 邓乾, 钱恩国, 吴忠纯, 等. 肺炎克雷伯菌肺炎的CT影像表现[J]. 影像研究与医学应用, 2023, 7(22):158-160.
[41] 李淑艳. 基于影像学特征在碳青霉烯类耐药铜绿假单胞菌感染中的诊断及重症风险分析[D]. 广州:广州医科大学, 2024.
[42] 段智梅, 魏腾陈, 王凯飞, 等. 军团菌肺炎临床分析并文献复习[J]. 解放军医学院学报, 2022, 43(3):284-290.
[43] 张金娥, 赵振军. 210例耐甲氧西林金黄色葡萄球菌肺炎的CT征象分析[J]. 临床放射学杂志, 2018, 37(8):1298-1302.
[44] 王东侠. 成人支原体肺炎的临床和CT影像特征[J]. 当代临床医刊, 2022, 35(5):68-69.
[45] LIN YT, LIN HH, CHEN CH, et al.Identification of Staphylococcus aureus, Enterococcus faecium, Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii from Raman spectra by Artificial Intelligent Raman Detection and Identification System (AIRDIS) with machine learning[J]. J Microbiol Immunol Infect, 2025, 58(1):77-85.
[46] FERETZAKIS G, SAKAGIANNI A, LOUPELIS E, et al.Using Machine Learning to Predict Antimicrobial Resistance of Acinetobacter Baumannii, Klebsiella Pneumoniae and Pseudomonas Aeruginosa Strains[J]. Stud Health Technol Inform, 2021, 281:43-47.
[47] 王晓兢, 姚艳玲, 李文玉, 等. 基于大数据挖掘下多重耐药菌风险评估的研究价值[J/CD]. 新发传染病电子杂志, 2024, 9(1):31-36.
[48] HU X, ZHAO Y, HAN P, et al.Novel Clinical mNGS-Based Machine Learning Model for Rapid Antimicrobial Susceptibility Testing of Acinetobacter baumannii[J]. J Clin Microbiol, 2023, 61(5):e0180522.
[49] LIU G, CATACUTAN DB, RATHOD K, et al.Deep learning-guided discovery of an antibiotic targeting Acinetobacter baumannii[J]. Nat Chem Biol, 2023, 19(11):1342-1350.
[50] 许铎耀, 杨翰, 权申文, 等. 基于肺部不同影像学特征构建耐多药肺结核患者预测模型[J/CD]. 新发传染病电子杂志, 2023, 8(6):14-21.